Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lampalizumab Exposure-Response Study in Geographic Atrophy
NCT02288559Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2015
- Primary completion
- Jun 2017
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of lampalizumab in geographic atrophy (GA) (4 arms), sponsored by Genentech. Primary endpoint: Change From Baseline in Geographic Atrophy (GA) Area at 24 weeks. Started Mar 2015; status: completed.
02
Drugs
lampalizumab
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT02288559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288559.